nadofaragene firadenovec + gemcitabine + docetaxel

This is a combination of three agents: **nadofaragene firadenovec**, **gemcitabine**, and **docetaxel**. - **Nadofaragene firadenovec** is a non-replicating adenoviral vector-based gene therapy that delivers the human interferon alfa-2b gene directly to bladder epithelial cells, leading to local production of interferon alfa-2b, which induces anti-tumor, immunostimulatory, antiangiogenic, and apoptotic effects. It is primarily approved for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)[1][2][3][4]. - **Gemcitabine** is a nucleoside analog antimetabolite that inhibits DNA synthesis, primarily used as a chemotherapeutic for various malignancies including bladder cancer. - **Docetaxel** is a taxane-class chemotherapeutic that promotes microtubule stabilization, inhibiting cell division, widely used in solid tumors including bladder carcinoma. Combination intravesical therapy with gemcitabine and docetaxel (sometimes alongside additional agents such as nadofaragene firadenovec) is being explored in investigational settings for BCG-unresponsive bladder cancer to potentially enhance efficacy through synergistic anti-tumor mechanisms.